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Despite showing promise in preclinical models, anti–
Staphylococcus aureus vaccines have failed in clinical trials.
To date, approaches have focused on neutralizing/opsoniz-
ing antibodies; however, vaccines exclusively inducing cellu-
lar immunity have not been studied to formally test whether
a cellular-only response can protect against infection. We
demonstrate that nasal vaccination with targeted nanoparti-
cles loaded with Staphylococcus aureus antigen protects
against acute systemic S. aureus infection in the absence of
any antigen-speciﬁc antibodies. These ﬁndings can help
inform future developments in staphylococcal vaccine devel-
opment and studies into the requirements for protective im-
munity against S. aureus.
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Infections caused by antibiotic-resistant Staphylococcus aureus
are causing a global epidemic and present an urgent and unmet
need for effective vaccines [1]. Although a number of vaccines
were effective in preclinical challenge models, these subse-
quently failed in clinical trials [2] due at least in part to a lack of
insight into what constitutes protective immunity in the human
host. Until recently, anti–S. aureus vaccine approaches have
focused on the induction of neutralizing/opsonizing antibodies,
but there is increasing evidence that cellular immunity may be
equally or more important for protective immunity [3]. Indeed,
vaccines expanding T-helper type 1 (Th1) and T-helper type
17 (Th17) cells conferred protection in murine models of
S. aureus infection [4]. However, to date, systems that exclusive-
ly induce cellular immunity in the absence of humoral immu-
nity have not been studied to determine if a cellular-only
response can protect against systemic staphylococcal infection.
Because mucosal vaccination can potentially stimulate an
immune response both at the mucosae and systemically, and
has the advantage of being needle-free, our objective was to
design a mucosal S. aureus vaccine that selectively promoted
cellular immunity. Initiating an immune response at the
mucosae is hindered by several factors, particularly poor uptake
across epithelial barriers. Targeting mucosal antigen-sampling
microfold (M) cells is a promising approach to address inefﬁ-
cient transepithelial vaccine uptake [5].Ulex europaeus aggluti-
nin I (UEA-1), a fucose binding lectin from gorse, binds to [6]
and can enhance the transcytosis of nanoparticles across
M cells [7], potentially delivering the attached antigen to sube-
pithelial dendritic cells. Thus, we investigated the potential of
targeting particulate vaccines to M cells with UEA-1 and a
UEA-1 peptidomimetic (UEA-1m) [8].
METHODS
Animals
Female BALB/c and C57BL/6 mice were obtained from Harlan
Laboratories and Charles River Laboratories and were used at
8–16 weeks of age. Animals were maintained in a speciﬁc path-
ogen-free environment at the TCD Bioresource facility. All
mice were maintained according to European Union regula-
tions, and experiments were performed under license from
the Irish Department of Health and Children and with ap-
proval from the Trinity College Dublin Bioresources Ethics
Committee.
Materials
Streptavidin-coated polystyrene nanoparticles (300–390 nm)
were supplied by Spherotech Inc and Corpuscular Inc.
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Figure 1. Lectin-targeted mucosal delivery of nanoparticulate antigens induces strong T-cell responses in the absence of a humoral response. Mice
were immunized intranasally on days 1, 14, and 28 with phosphate-buffered saline (PBS) only as a control or ovalbumin (OVA; 10 µg) with or without Ulex
europaeus agglutinin I peptidomimetic (UEA-1m; 10 µg), attached to nanoparticles (NP). A, Antigen-speciﬁc responses by cells isolated from the cervical
lymph nodes were determined on day 35, by ex vivo restimulation with OVA (500 µg/mL) for 72 hours, and subsequent enzyme-linked immunosorbent
assay (ELISA) to determine cytokine production. Mean ± SEM. *P < .05 vs nontargeted particles; 1-way analysis of variance (ANOVA) and Tukey posttest
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Biotinylated UEA-1m (synthesized by Polypeptide), and oval-
bumin (OVA) antigen (Sigma) were both provided as lyophilized
powders and reconstituted in endotoxin-free phosphate-
buffered saline (PBS). The A domain of clumping factor A
(ClfA; amino acids 40–559) was expressed as a hexahistidine-
tagged recombinant protein and puriﬁed by Ni2+ chelate chro-
matography. Both OVA and ClfA antigens were biotinylated
with the EZ-Link Sulfo-NHS-LC biotinylation kit (Thermo Sci-
entiﬁc). Cytokine and antibody enzyme-linked immunosorbent
assay (ELISA) detection kits were obtained from R&D Systems,
BD Pharmingen, and BioLegend. Complete RPMI (cRPMI)
comprised RPMI 1640 (BioSera), 10% fetal calf serum
(BioSera), 1% penicillin-streptomycin (Invitrogen), and 1% L-
glutamine (Invitrogen). Fluorescently conjugated antibodies for
ﬂow cytometry were purchased from BD Biosciences (anti–in-
terleukin 17A [IL-17A] PerCP-Cy 5 clone TC11-18H10) and
eBiosciences (anti–interferon [IFN]–γ PE Cy7 clone XMG 1.2).
Quil A saponin was obtained from Brenntag, and the fraction-
ated derivative of Quil A (QS21) was provided by the Vaccine
Formulation Laboratory in Lausanne, Switzerland.
Vaccine Formulations
Biotinylated antigen (OVA or ClfA) and biotinylated UEA-1m
were incubated with streptavidin-coated polystyrene nanoparti-
cles for 1 hour at room temperature in sodium phosphate
buffer (pH 5.5). Fifty micrograms of OVA was administered by
oral vaccination, but 10 µg OVA and 2 µg ClfA was sufﬁcient
for intranasal vaccine formulations (adequate quantity to
induce a cellular response to targeted nanoparticles). UEA-1m
was incorporated at 10 µg per vaccine formulation (attached
to nanoparticles). Protein attachment was determined by
bicinchoninic assay (Thermo Scientiﬁc) of the supernatant,
and the particles were resuspended in PBS (pH 7.4) before use.
The contents of each formulation are detailed in the Figure
legends.
Immunization Strategies
Groups of mice (n = 5) were immunized orally on 3 consecutive
days (days 0, 1, and 2) and boosted 3 weeks later (days 21, 22,
and 23) with PBS only, OVA (50 µg) nanoparticles, or OVA
(50 µg) + UEA-1m (50 µg) nanoparticles. Mice were immu-
nized intranasally on days 0, 14, and 28 by dropping the
vaccine formulation (20 µL maximum volume containing OVA
or ClfA antigen in solution or particulate form) onto each
nostril and allowing the animal to inhale the vaccine. Group
sizes for mucosal vaccinations and challenge were determined
based on our previous experience and published reports [9, 10].
Blood samples were taken from the tail vein before each immu-
nization for analysis of antibody production. Tissues were iso-
lated after killing, the cells isolated by mechanical disruption,
and restimulated with antigen in vitro.
Measuring the Cellular and Humoral Response to Antigen
Antigen-speciﬁc antibody titers in the serum and nasal washes,
and cytokine secretion by restimulated lymphocytes (cultured
for 72 hours) were determined by sandwich ELISA as described
previously [9]. All samples were analyzed in triplicate. Cytokine
production by CD3+CD4+ and CD3+CD8+ T cells was detected
by restimulating the cells for 6 hours in vitro in cRPMI with or
without antigen. Brefeldin A (10 µg/mL; Sigma) was added to
the culture after 1 hour to prevent cytokine export from the
cells. After 6 hours the T cells were labeled with anti-CD3, anti-
CD4, and anti-CD8 ﬂuorophore-conjugated antibodies. Fol-
lowing ﬁxation and permeabilization with FIX&PERM (ADG
Bioresearch GmbH), intracellular IFN-γ and IL-17 were
labeled. Data were acquired with a FACSCanto II (BD Biosci-
ences) and analyzed using FlowJo software (TreeStar Inc).
Measuring Neutralizing Antibodies in Serum
The presence of neutralizing antibodies was determined by
testing the ability of serum from immunized mice to inhibit the
Figure 1 Continued. (n = 5). B, Serum samples harvested from blood taken on day 35 were analyzed for the presence of OVA-speciﬁc immunoglobulin G
(IgG). Each data point represents an individual animal. C, Nasal delivery of QS21-adjuvanted OVA promotes humoral immunity. Mice were immunized intra-
nasally on days 1, 14, and 28 with PBS or OVA (10 µg) either in solution or conjugated to nanoparticles with UEA-1m (10 µg), or with OVA and Quil A
saponin or a puriﬁed derivative of Quil A (QS21), both at 10 µg per dose. Blood and nasal cavity washes were taken on day 35. Antigen (OVA)–speciﬁc anti-
body titers were determined by ELISA. Each data point represents an individual animal (n = 5); the black bars denote the mean. *P < .05, **P < .01, and
***P < .001 vs antigen alone; 1-way ANOVA and Tukey posttest (n = 5). D–H, Nasal immunization with Staphylococcus aureus clumping factor A (ClfA).
Female C57BL/6 mice were immunized intranasally on days 1, 14, and 28 with ClfA (2 µg) attached to nanoparticles alone or targeted with UEA-1m (10
µg). Antigen-speciﬁc responses by cells isolated from the spleen were determined on day 35, by ex vivo restimulation with ClfA (10 µg/mL), and subse-
quent ELISA (D) and intracellular staining (E and F ) to determine cytokine production. Antigen-speciﬁc responses by splenic CD3+CD8+ and CD3+CD4+ T
cells were assessed by ex vivo restimulation of the cells with ClfA for 6 hours, and subsequent ﬂow cytometric analysis of interferon (IFN)-γ and interleukin
17 (IL-17)–producing cells. Representative dotplots showing the percentage of IFN-γ or IL-17–producing T cells. Unstimulated cells are on the left of each
panel, ClfA-stimulated cells on the right. Pooled data showing the fold change in percentage of cytokine-producing T cells in the spleen (compared to unsti-
mulated control). G, Anti-ClfA IgG antibody titers were assessed by ELISA in day 35 serum and nasal wash samples. The presence of neutralizing antibod-
ies was determined by measuring the ability of serum to inhibit ClfA-mediated S. aureus adherence to ﬁbrinogen. Staphylococcus aureus was
preincubated with serum, and adherence to ﬁbrinogen was calculated as a percentage of values measured in control wells lacking serum. Data are repre-
sentative of 2–3 independent experiments. Each data point represents an individual animal; the black bars denote the mean. ***P < .001 by 1-way ANOVA
and Tukey posttest (n = 5).
BRIEF REPORT • JID 2014:209 (1 May) • 1481
adherence of S. aureus to ﬁbrinogen. Microtiter plates were
coated with ﬁbrinogen (2 µg/mL) overnight at 4°C and blocked
for 2 hours at 37°C with 5% (w/v) bovine serum albumin.
Staphylococcus aureus PS80 was grown to stationary phase,
washed, and incubated with mouse serum (1:60 dilution) for 30
minutes at room temperature before being added to the wells of
a ﬁbrinogen-coated plate and incubated for 1.5 hours at 37°C.
After washing with PBS, adherent cells were ﬁxed with formal-
dehyde (25% v/v) and stained with crystal violet, and the A570
nm was measured. Adherence was expressed as a percentage of
bacterial adherence in the absence of serum, and percentage of
inhibition was determined by subtracting the percentage adher-
ence values from 100.
Staphylococcus aureus Infection
Staphylococcus aureus PS80 has been previously described [10].
Staphylococci were cultivated from frozen stocks on Columbia
agar with 2% NaCl. Bacteria were resuspended to an appropri-
ate concentration in PBS. Nasally immunized C57BL/6 mice
were infected with a sublethal inoculum of S. aureus (5 × 108
colony-forming units [CFU]) by intraperitoneal injection, on
day 36, and were sacriﬁced 3, 24, and 72 hours postinfection (5
mice per treatment group, per timepoint; group size was deter-
mined through optimization of the challenge model [10]). At
speciﬁc timepoints postchallenge, the peritoneal cavity was
lavaged with sterile PBS and the kidneys and spleens were har-
vested and homogenized in PBS. Serial dilutions of the perito-
neal exudates and organ homogenates were prepared and plated
onto tryptic soy agar to determine the numbers of S. aureus
CFU. Serum was collected from each mouse 1 day prior to each
vaccination for analysis of antibody titers. To quantify phago-
cyte inﬁltration, total leukocytes isolated from the peritoneal
exudates were enumerated using a hemocytometer and were
then stained with monoclonal antibodies against neutrophil
(CD11b+Ly6G+F4/80−) and macrophage (CD11b+Ly6G−F4/
80+) surface markers before analysis by ﬂow cytometry (BD
FACSCalibur).
Statistical Analysis
Data are presented as mean (±SEM) from 5 mice per experi-
mental group, tested individually in triplicate. P < .05, P < .01,
and P < .001 denote statistical signiﬁcance between groups by
1-way analysis of variance and Tukey posttest, or by 1-tailed
unpaired Student t test, as speciﬁed in the Figure legends.
RESULTS AND DISCUSSION
Nasal vaccination with UEA-1m–targeted, antigen (OVA)–
loaded nanoparticles (300–390 nm diameter) promoted en-
hanced antigen-speciﬁc T-cell responses compared to antigen
conjugated to nontargeted particles (Figure 1A). The most
striking ﬁnding was the Th1- and Th17-biased response elicited
by targeted nanoparticles (Figure 1A), without the induction
of any detectable antigen-speciﬁc serum immunoglobulin
G (IgG) (Figure 1B). Similarly, oral vaccination with UEA-
1m–targeted nanoparticles enhanced antigen-speciﬁc cellular
responses (Supplementary Figure 1), compared to untargeted
nanoparticles in the absence of a detectable antibody response.
In contrast, antibodies were readily induced both systemically
(serum IgG) and locally (nasal wash immunoglobulin A [IgA])
following intranasal administration of OVA in combina-
tion with Quil A, a potent saponin adjuvant [11], or QS21
(Figure 1C), an adjuvant active fraction of Quil A that displays
reduced toxicity [11]. Our ﬁndings support a report that UEA-
1 targeting of a nasal human immunodeﬁciency virus vaccine
elicited enhanced cellular responses [12] but differs in that our
system did not induce any local or systemic humoral immunity.
Having identiﬁed a mucosal adjuvant formulation that selec-
tively promoted T-cell responses, we generated a model anti–
S. aureus vaccine, based on UEA-1m–targeted nanoparticles
coupled with the S. aureus surface antigen ClfA, and investigat-
ed its efﬁcacy in protection against systemic S. aureus infection.
ClfA is an important S. aureus virulence factor, which pro-
motes bacterial adherence to ﬁbrinogen [13].Whereas immuni-
zation of mice with recombinant ClfA A domain formulated
with Freund’s complete adjuvant induced protective humoral
immunity [13], protection was IL-17A–dependent following in-
jection of the antigen in alum adjuvant [14]. These reports
highlight the promise of this ubiquitously expressed staphylo-
coccal surface protein as a candidate antigen for the induction
of protective cell-mediated immunity. In line with this, a
vaccine based on a Candida albicans surface protein with struc-
tural similarity to ClfA [15] induced protective anti–S. aureus
immunity that was critically dependent on the induction of
Th1 and Th17 responses [4].
Initially, we investigated whether UEA-1m–targeted ClfA-
loaded nanoparticles could promote antigen-speciﬁc T-cell re-
sponses in the absence of antibodies. As in the case of OVA,
UEA-1m targeting signiﬁcantly enhanced ClfA-speciﬁc IFN-γ
and IL-17 production (Figure 1D). Splenic CD3+CD4+ and
CD3+CD8+ T cells from targeted nanoparticle-vaccinated mice
produced IFN-γ and IL-17 upon in vitro restimulation with
ClfA, as reﬂected in an increased percentage of antigen-speciﬁc
cytokine-producing T cells and a greater fold increase in cytokine-
producing T cells vs controls (Figure 1E, F). Anti-ClfA antibodies
were undetectable in serum samples from animals vaccinated
with ClfA-loaded, UEA-1m–targeted nanoparticles, whereas
high titers of antigen-speciﬁc serum IgG, IgA (Figure 1G), and
function-neutralizing antibodies capable of blocking the adher-
ence of ClfA-expressing bacteria to ﬁbrinogen were elicited by
vaccination with ClfA and QS21 (Figure 1H).
Having established the ability of the ClfA-loaded, UEA-
1m–targeted nanoparticles to elicit ClfA-speciﬁc cellular immune
responses in the complete absence of any speciﬁc humoral
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Figure 2. The induction of cellular immunity by a nasal targeted nanoparticulate Staphylococcus aureus vaccine is sufﬁcient for clearance of a systemic
S. aureus infection. A, Immunization strategy. Mice were immunized intranasally on days 1, 14, and 28 with phosphate-buffered saline (PBS) or with clumping
factor A (ClfA; 2 µg) and Ulex europaeus agglutinin I peptidomimetic (UEA-1m; 10 µg) attached to nanoparticles (NP). Mice were sacriﬁced at time 0 (day 35,
before infection), and at 3, 24, and 72 hours after intraperitoneal infection with 5 × 108 colony-forming units (CFU) S. aureus (strain PS80). Data are represen-
tative of 2 independent experiments. B and C, Bacterial counts. The peritoneal exudate, kidneys, and spleen were harvested at each time point, homogenized,
and cultured, and CFUs were determined. CFU burden is expressed as the mean ± SEM over time (n = 5, top panel), and in each tissue at 72 hours postinfec-
tion. C, Statistical signiﬁcance between groups is denoted by *P < .05 and **P < .01 (1-tailed unpaired Student t test). D and E, Antibody responses following
challenge. Anti-ClfA immunoglobulin G (IgG) antibody titers were determined by enzyme-linked immunosorbent assay on serum samples recovered at each
timepoint postinfection. The presence of neutralizing antibodies was determined by measuring the ability of serum to inhibit ClfA-mediated S. aureus adher-
ence to ﬁbrinogen. Staphylococcus aureus was preincubated with serum, and adherence to ﬁbrinogen was calculated as a percentage of values measured in
control wells lacking serum. Each data point represents an individual animal (n = 5); the black bars denote the mean. ***P < .001 by 1-way analysis of vari-
ance and Tukey posttest. F, Phagocytes at the site of infection. The total numbers of peritoneal macrophages and neutrophils in control and vaccinated mice
were determined by ﬂow cytometry at 3, 24, and 72 hours following infection. *P < .05 by 1-tailed unpaired Student t test (n = 5).
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immunity, we next determined the ability of this vaccine to
induce protective immunity against systemic S. aureus infec-
tion. Groups of mice were nasally immunized with either ClfA
on UEA-1m–targeted nanoparticles or ClfA with QS21 prior to
intraperitoneal challenge with a sublethal dose of S. aureus
(Figure 2A). Bacterial load both locally at the site of infection
(peritoneal cavity) and systemically (kidneys and spleen) was
reduced in both vaccinated groups over the course of infection
(Figure 2B, Supplementary Figure 2), with a signiﬁcant (ap-
proximately 2 log) reduction in systemic bacterial dissemina-
tion to the kidneys at 72 hours postinfection, in animals
receiving either vaccine compared to unvaccinated control
animals (Figure 2C, Supplementary Figure 2).
Antigen-speciﬁc serum antibody titers induced by the QS21-
adjuvanted vaccine remained stable over the course of immuni-
zation, and neutralizing antibodies were still present 72 hours
postinfection but were completely undetectable in animals re-
ceiving the UEA-1m–targeted nanoparticle vaccine (Figure 2D
and E). In addition to promoting T-cell responses (Figure 1D),
immunization with ClfA on UEA-1m–targeted nanoparticles
also increased local inﬁltration of neutrophils and macrophages
to the peritoneal cavity (Figure 2F ) at 72 hours postinfection
compared to unvaccinated animals. In contrast, there was no
signiﬁcant increase in phagocyte inﬁltration to the peritoneal
cavity in animals that received the QS21-adjuvanted vaccine
(Supplementary Figure 2C).
Remarkably, these data demonstrate that a targeted nasal
vaccine promotes clearance of an acute S. aureus systemic infec-
tion, but also that a purely cellular response is sufﬁcient for this
protection. This is the ﬁrst formal demonstration that vaccine-
induced S. aureus antigen-speciﬁc cellular immunity in the
absence of detectable antibody responses can protect against
staphylococcal infection and expands upon previously pub-
lished work indicating the importance of cellular immunity
in vaccine-induced protection against S. aureus infection
[4, 15]. Our targeted mucosal vaccine approach will prove a
valuable tool not only in dissecting protective immunity to
S. aureus but also for other bacterial infections where Th1 and
Th17 responses have been shown to contribute to protective
immunity, including Bordetella pertussis and Streptococcus
pneumoniae.
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